Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues
Authors' conclusion
Advanced RAS-driven follicular-derived thyroid cancers seem to exhibit an aggressive behavior, particularly in ATC, in which prognosis remains poor despite expert multidisciplinary care. Advances in RAS-targeted therapies offer hope for improved therapeutic options.
Study context
- Population
- Individuals with RAS-altered DTC or anaplastic (ATC) identified before kinase inhibitor exposure, MD Anderson Cancer Center, January 2015–June 2023
- Participants
- 120 vs 71
- Exposure
- DTC vs ATC
- DTCn = 120
- ATCn = 71
- Outcome
- Clinical and molecular characteristics
Methodological detailsretrospective chart review, single-centre
- Retrospective chart review
- Single-centre
Main finding
As reported in the abstract
NRAS alteration (most common), mainly at residue Q61
Observational data: associations, not effects.
Secondary outcomes
Brain metastases among patients undergoing brain imaging
| Outcome | DTC | ATC |
|---|---|---|
| Median OS | median 15.2 years | median 7.5 months |
- Brain metastases among patients undergoing brain imaging — Overall
- 22%
- Median overall survival (OS): median follow-up 8.4 years in DTC, 36.4 months in ATC
Systemic therapy in DTC
- Received ≥1 line of systemic therapy
- 49%
- Lenvatinib (most common)
- 66%
- Median time to systemic therapy from diagnosis
- 3.5 years
- Median OS from therapy initiation
- 6.0 years
Factors associated with mortality in ATC
- Stage IVC, HR
- 6.78
- Neck surgery, HR
- 0.29
- Exposure to immunotherapy, HR
- 0.13
- Significantly associated with mortality
Original publication
Characterization of Advanced RAS -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. J Clin Endocrinol Metab. Published 26 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →